Natera shared on X:
“Join us for a practical, APP-led discussion on integrating Prospera Heart with DQS testing into transplant care.
- Explore how two different transplant centers define the role of an APP in this evolving world of post-transplant care.
- Discover the benefits of integrating Prospera into the post-transplant workflow.
- Discuss real-world cases where a non-invasive alternative to surveillance biopsy can help drive clinical decisions.
Whether you’re considering using dd-cfDNA testing or looking to strengthen how it’s used in your center, you’ll leave with actionable insights on how to integrate Prospera into practice.”
About Prospera Heart
Prospera Heart is a non-invasive blood test developed by Natera to assess organ health and monitor for allograft rejection in heart transplant recipients.
In solid organ transplantation, early detection of graft injury is essential for preventing organ failure, adjusting immunosuppressive therapy, and improving long-term patient outcomes. Historically, monitoring graft health has relied on routine invasive endomyocardial biopsies, which carry clinical risks, cause patient discomfort, and present scheduling challenges. Prospera Heart offers a precision-medicine alternative that measures donor-derived cell-free DNA in the recipient’s bloodstream.
The addition of Donor Quality Score testing further enhances the clinical utility of Prospera Heart. DQS integrates donor-specific parameters and clinical risk factors into the analytical process, allowing clinicians to interpret dd-cfDNA levels within a more refined, individualized patient context. This risk-stratification model improves diagnostic accuracy and helps clinical teams differentiate baseline donor DNA variation from acute rejection events.
In modern post-transplant workflows, Advanced Practice Providers, such as nurse practitioners and physician assistants, play a central role in managing routine surveillance protocols.
Incorporating Prospera Heart into APP-led practices allows healthcare teams to establish reliable non-invasive monitoring schedules, reduce unnecessary surveillance biopsies, make informed choices about when a diagnostic biopsy is strictly necessary, and dynamically optimize immunosuppression regimens to protect the allograft.
You can also read: Natera’s Signatera MRD Test Gains Broader Medicare Coverage for Liver Cancer Surveillance
